Ansell Limited (ASX:ANN): FY26 Financial Performance and Manufacturing Developments

Aditi Sarkar

20 October 2026 04:53 PM AEDT

Ansell Limited (ASX:ANN): FY26 Financial Performance and Manufacturing Developments

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Ansell Limited (ASX:ANN) reported FY26 sales of US$2,140.2 million.
FY26 adjusted EBIT reached US$321.9 million, with a 15.0% adjusted EBIT margin.
The company opened a surgical-glove manufacturing facility in Kovai, India, in September 2026.
Ansell opened an additional Xperience & Innovation Studio near Coimbra, Portugal, in September 2026.

Ansell Limited manufactures and distributes personal protective equipment used in healthcare, laboratories and industrial workplaces, including surgical gloves and products designed for mechanical and chemical hazards. The group reported its FY26 financial results in August and subsequently announced manufacturing and product-development initiatives. On 20 October 2026, Ansell Limited (ASX:ANN) was trading at AUD 45.90, down 0.97% for the session.

Company Business

Ansell operates across healthcare and industrial protection markets, supplying customers in more than 100 countries. Its products include surgical and examination gloves, cleanroom protection, industrial hand protection and other workplace safety products. Healthcare demand reflects clinical and laboratory purchasing requirements, while industrial applications extend to manufacturing, maintenance and specialised work environments. These activities expose the group to different procurement cycles, customer specifications and regulatory obligations.

The company’s manufacturing network and distribution arrangements serve customers across multiple regions. Product suitability, material specifications and compliance requirements influence purchasing decisions in its end markets. Ansell Limited (ASX:ANN) therefore manages both the development of protective equipment and the availability of products through its supply chain. The mix of healthcare and industrial customers is relevant when assessing variations in sales volumes and operating costs.

Recent Development

In August 2026, Ansell announced its full-year results for the period ended 30 June 2026. The company said sales growth accelerated in the second half, reflecting improved volume trends. Its update also discussed pricing and sourcing measures intended to address US tariff effects and increases in input costs. Those developments provide context for the earnings and margin figures reported for the year.

Recent Development

In September 2026, Ansell inaugurated a manufacturing site in Kovai, India, for surgical gloves. The company said production for the local market had already begun, with further capacity expected to become operational in subsequent months. The facility is intended to support customers in India and other markets, including the United States and parts of Europe. For Ansell Limited (ASX:ANN), the site adds another manufacturing location to its surgical product supply network.

Recent Development

Later in September, the group announced the opening of another Ansell Xperience & Innovation Studio near Coimbra, Portugal. The location is designed to support customer engagement and testing of safety applications. The announcement adds to the company’s 2026 operational updates but does not itself establish a quantifiable earnings contribution.

Financial Performance and Sector Context

Ansell reported FY26 revenue of US$2,140.2 million, an increase of 6.8% on a reported basis. Organic constant-currency sales growth was 5.0%. Adjusted earnings before interest and tax reached US$321.9 million, increasing 14.1% on a reported basis. Its adjusted EBIT margin was 15.0%, compared with 14.1% in the preceding comparative period, as disclosed in the FY26 results.

Financial Performance and Sector Context

The company reported adjusted earnings per share of US148.6 cents for FY26. Adjusted measures exclude specified items and should not be treated as interchangeable with statutory profit. Sales growth and the balance between product prices, manufacturing costs and operating expenses remain relevant to interpreting earnings. Ansell Limited (ASX:ANN) also operates in markets affected by hospital procurement budgets, industrial activity, product standards, foreign-exchange movements and international trade policy.

Risks to Consider

Operating risks include changes in raw-material and energy prices, interruptions in manufacturing, logistics constraints and the timing of customer orders. Trade tariffs and foreign-exchange movements may affect reported costs and revenue. Healthcare products require compliance with applicable product and quality standards; changes in those requirements can add costs. The ramp-up of new manufacturing capacity also introduces execution and utilisation considerations.

What to Watch Next

Following the FY26 results, disclosures concerning production utilisation at the Indian facility and additional manufacturing capacity will help establish how the investment develops. Updates on order patterns in healthcare and industrial markets, selling prices and supply-chain productivity will also provide operating context. The company has scheduled its 2026 annual general meeting for November, with its next half-year reporting period due in 2027.

Key Insights

Ansell Limited (ASX:ANN) entered the new financial year following reported growth in FY26 revenue and adjusted EBIT, alongside an improvement in adjusted operating margin. Its 2026 announcements also included a surgical-glove factory opening in India and an innovation facility in Portugal. Subsequent reporting can clarify whether changes in demand, manufacturing capacity, tariffs and costs alter the group’s operating profile. The quoted October share price should not be interpreted as evidence of the causes of those business changes.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.